Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial.

Name: Kaimen Rigor review — Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial.
Item: Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial.
Rating: 100
Author: Alpha1

Kopetz S, Murphy DA, Pu J, Ciardiello F, Desai J, Van Cutsem E, Wasan HS, Yoshino T, Saffari H, Zhang X, Hamilton P, Xie T, Yaeger R, Tabernero J

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 2.75★ (Weak), 0 critical, 1 high issue for “Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Read alongside

Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial.

Kopetz S, Murphy DA, Pu J, Ciardiello F, Desai J, Van Cutsem E, Wasan HS, Yoshino T, Saffari H, Zhang X, Hamilton P, Xie T, Yaeger R, Tabernero J

Read full text (PMC)

DOI

10.1038/s41591-024-03235-9

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/db08a7c9-3aab-4dc3-855e-6c6976ba67f2" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/db08a7c9-3aab-4dc3-855e-6c6976ba67f2/badge" alt="Kaimen Rigor review — 2.75★ (Weak), 0 critical, 1 high issue for “Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

f85f1bd1b818bf08bae6e62fef33f256349d4d4fe0b0e38fe343c468f60e3e98

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial.

Kopetz S, Murphy DA, Pu J, Ciardiello F, Desai J, Van Cutsem E, Wasan HS, Yoshino T, Saffari H, Zhang X, Hamilton P, Xie T, Yaeger R, Tabernero J

Paper source

Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
CitationsUnresolved reference−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy claim is based on overall survival (OS) from the BEACON CRC trial, which is a hard clinical outcome. However, the biomarker analyses presented in this manuscript focus on surrogate endpoints such as immune gene signatures, cytolytic score, and molecular subtypes as predictors of OS benefit. These surrogates are not validated as substitutes for clinical outcomes, and the manuscript does not provide evidence linking these biomarkers to clinical benefit beyond exploratory associations. The claim that 'higher immune signatures showed a trend towards increased OS benefit' is based on a surrogate (immune signature) without established validation for predicting clinical outcomes in this context.
“Tumors with higher immune signatures showed a trend towards increased OS benefit with Enco+Bini+Cetux.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The manuscript reports hazard ratios for OS benefit in subgroups, but the primary effect size for the efficacy claim is not explicitly anchored to a minimal clinically important difference or a meaningful magnitude. For example, the HR for OS with Enco+Cetux versus control in TP53 wild-type is 0.37, but the manuscript does not discuss whether this is clinically meaningful. Additionally, the biomarker associations are exploratory and not presented with effect sizes that are clearly clinically significant. The manuscript states 'trend towards increased OS benefit' without providing a clear magnitude of benefit that is clinically meaningful.
“Patients with wild-type TP53 showed greater OS benefit with Enco+Cetux (hazard ratio (HR), 0.37 (95% confidence interval (CI), 0.224–0.627) for wild type and 0.76 (95% CI, 0.547–1.060) for mutant; P interaction = 0.0276)”
Find in source
03Other integrity concern
mediumAuthenticityreviewer-assessedFull detail
Trial NCT04017650 was first submitted to ClinicalTrials.gov on 2019-07-10, after the registered study start date of 2019-06-14. Retrospective registration means the protocol and outcomes were not on the public record before the study ran, which is what prospective registration exists to establish.
NCT04017650
reviewer’s wording

Findings by category

101ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 103AuthenticityData authenticity concerns 04DisclosureNone found 105AvailabilityBroken references and links 06Copyedit6 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted, prespecified retrospective biomarker analysis of a phase 3 randomized trial, with strong reporting of ethics, resources, and data availability. Minor gaps include lack of randomization method detail, no power analysis for biomarker endpoints, and no explicit reporting guideline, but these do not undermine the overall rigor.

Both reviewers classified the study as interventional, which is adopted. The analysis is a retrospective biomarker sub-study of an interventional trial; the primary trial design is interventional. The statistics verification recomputed only 2 tests (both consistent); other statistics were not machine-verified. The citation check flagged one reference as not found in registry.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

Overstated conclusions

2 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

7 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

1 finding · worst medium

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

2 integrity concerns flagged (0 high).

Reporting gaps

None found

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Checked — nothing surfaced.

Eight Dimensions8 pass

The introduction cites prior work on BRAF-V600E mutations, the BEACON CRC trial, and previous studies on acquired resistance alterations. It clearly states the objective to identify molecular correlates of clinical outcomes and define resistance mechanisms. The paper acknowledges gaps in prior research, such as the lack of large randomized trials studying molecular subtypes and resistance mechanisms with BRAF inhibitor combinations.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior research on BRAF-V600E-mutant mCRC, the BEACON CRC trial results, and the need to understand biomarkers of response and resistance.

Evidence

paraphrase[Introduction, paragraph 1]

“BRAF-V600E mutations occur in approximately 10% of tumors in patients with mCRC and are associated with poor prognosis relative to wild-type BRAF tumors.”

“The objective of this analysis was to identify molecular correlates of clinical outcomes and define resistance mechanisms acquired following treatment.”

Introduction ¶3Find in source

“To our knowledge, clinical associations with molecular subtypes and mechanisms of acquired resistance following treatment with a BRAF inhibitor plus an anti-EGFR antibody, with or without a MEK inhibitor, versus conventional cytotoxic chemotherapy plus an anti-EGFR antibody, have not been studied in large, randomized trials.”

Introduction ¶2Find in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise by citing prior work on BRAF-V600E-mutant mCRC, BEACON CRC results, and known resistance mechanisms, and logically links this to the study's objectives.

Evidence

paraphrase[Introduction, paragraph 1]

“BRAF-V600E mutations occur in approximately 10% of tumors in patients with mCRC and are associated with poor prognosis relative to wild-type BRAF tumors.”

Introduction ¶2Find in source

“The objective of this analysis was to identify molecular correlates of clinical outcomes and define resistance mechanisms acquired following treatment.”

Introduction ¶2Find in source

The BEACON CRC trial is a randomized, open-label phase 3 trial with 1:1:1 randomization. Randomization method is not explicitly described but is standard for a phase 3 trial. Blinding is described for PFS assessment (blinded independent central review). Power analysis for the primary endpoints is referenced to previous publications, but not for the biomarker analyses. Inclusion/exclusion criteria are described. Outlier handling is addressed through exclusion criteria for ctDNA analyses. Controls are the comparator arm (Cetux+chemotherapy). Independent replication is not applicable as this is a single pivotal trial.

Sub-criteria

controlsADEQUATE

power analysisINADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodINADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The study design is rigorous, with clear randomization, blinding for PFS assessment, and a prespecified analysis plan, though some elements like power analysis for biomarker endpoints are not detailed.

Evidence

“patients were assigned randomly 1:1:1 to receive encorafenib, binimetinib and cetuximab (Enco+Bini+Cetux); encorafenib and cetuximab (Enco+Cetux); or investigators’ choice of either cetuximab with irinotecan or FOLFIRI (control).”

MethodsFind in source

“PFS, assessed by blinded independent central review and investigators, was defined as the time from randomization to the earliest documented disease progression or death due to any cause.”

MethodsFind in source

paraphrase[Methods, Statistical analysis]

“Calculation of the overall sample size required for the primary endpoints, statistical testing schemes and preplanned interim analysis was described previously.”

PASSReviewer 2· 85% conf

The study design is rigorous, with clear randomization, blinding for PFS assessment, and a prespecified analysis plan, though some elements like power analysis for biomarker analyses are not detailed.

Evidence

“The BEACON CRC trial was a global, multicenter, randomized, open-label phase 3 trial.”

MethodsFind in source

“PFS, assessed by blinded independent central review and investigators, was defined as the time from randomization to the earliest documented disease progression or death due to any cause.”

MethodsFind in source

paraphrase[Methods, Study design and participants]

“Patients with histologically or cytologically confirmed, mCRC with the BRAF-V600E mutation who had disease progression after one or two previous treatment regimens were enrolled.”

The paper reports sex and age in the patient characteristics (Supplementary Table). Demographics are described in the context of the trial population. Species/strain and housing conditions are not applicable as this is a human study. Health status is implied by inclusion criteria (mCRC with BRAF-V600E mutation).

Sub-criteria

demographicsINADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Biological variables are well reported, including sex, age, and demographics, though some details like race/ethnicity are not explicitly mentioned.

Evidence

paraphrase[Results, BEACON CRC biomarker analysis set]

“Paraphrase: Patient characteristics including sex and age are shown in Supplementary Table 1.”

absence[Results, BEACON CRC biomarker analysis set]

Demographics are not fully detailed in the main text.

PASSReviewer 2· 80% conf

Demographic and clinical characteristics are reported, including age, sex, and other baseline factors, though not all are detailed in the main text.

Evidence

“Heatmap of patient characteristics and molecular profiling coverage in the biomarker analysis set, across treatment arms.”

Figure 1BFind in source

“To assess the effect of potential confounders, results based on models with adjustment of key baseline covariates (Eastern Cooperative Oncology Group performance status, C-reactive protein, number of organs, tumor status, cetuximab source and previous use of irinotecan at randomization) are provided.”

Statistical analysisFind in source

The ethics statement explicitly states approval by institutional review boards or independent ethics committees at each center, compliance with the Declaration of Helsinki and ICH-GCP, and that all patients provided written informed consent. This meets all applicable criteria.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals are clearly documented, including IRB approval, informed consent, and regulatory compliance.

Evidence

paraphrase[Methods, Ethics statement]

“The trial was approved by the institutional review board or independent ethics committee at each center.”

“All patients provided written informed consent.”

EthicsFind in source

“conducted in accordance with the requirements of the regulatory authorities of each country and with the provisions of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Council on Harmonisation.”

EthicsFind in source

PASSReviewer 2· 95% conf

Ethical approval is clearly documented with a named ethics body, informed consent, and regulatory compliance.

Evidence

paraphrase[Methods, Ethics statement]

“The trial was approved by the institutional review board or independent ethics committee at each center.”

“All patients provided written informed consent.”

EthicsFind in source

paraphrase[Methods, Ethics statement]

“The trial was conducted in accordance with the requirements of the regulatory authorities of each country and with the provisions of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Council on Harmonisation.”

The investigational drugs (encorafenib, binimetinib, cetuximab) are named with doses and regimens. Sequencing platforms (Personalis ACE, GuardantOMNI) are identified with versions. Software tools are named with versions (e.g., CMSclassifier v.1.0.0, fgsea v.1.28.0). Antibodies, cell lines, and mycoplasma testing are not applicable as this is a clinical trial with no wet-lab assays.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Key resources are well identified, including the investigational drugs, sequencing platforms, and software tools, though some details like lot numbers are not provided.

Evidence

paraphrase[Methods, Study design and participants]

“Encorafenib was administered at a dose of 300 mg daily; binimetinib at 45 mg twice daily; cetuximab at 400 mg m−2 as an initial dose, then 250 mg m−2 weekly.”

paraphrase[Methods, WES and analysis]

“WES of formalin-fixed paraffin-embedded (FFPE) samples collected at patient screening was performed by Personalis Inc. using their Accuracy and Content Enhanced (ACE) Cancer Exome panel v.3 (sequenced on Illumina NovaSeq).”

paraphrase[Methods, Molecular subtyping]

“CMSs were assigned to each sample using the CMSclassifier package v.1.0.0.”

PASSReviewer 2· 85% conf

Key resources, including investigational drugs, sequencing platforms, and software, are identified with sufficient detail.

Evidence

paraphrase[Methods, Study design and participants]

“Encorafenib was administered at a dose of 300 mg daily; binimetinib at 45 mg twice daily; cetuximab at 400 mg m−2 as an initial dose, then 250 mg m−2 weekly.”

paraphrase[Methods, WES and analysis]

paraphrase[Methods, Molecular subtyping]

“CMSs were assigned to each sample using the CMSclassifier package v.1.0.0.”

Statistical tests are named (Cox proportional hazards, Wilcoxon rank-sum, Fisher exact, McNemar, etc.). Exact p-values are reported (e.g., P = 0.001). Effect sizes with confidence intervals are reported (e.g., HR, 0.37 (95% CI, 0.224–0.627)). Software is identified (SAS v.9.4, R v.4.0). Data presentation includes Kaplan-Meier curves and forest plots. Mathematical plausibility is not independently verified due to the complexity of the analyses.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedINADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 80% conf

Statistical methods are appropriate and well described, with exact p-values and effect sizes with confidence intervals reported, though some assumptions are not explicitly verified.

Evidence

paraphrase[Methods, Statistical analysis]

“Cox proportional hazards models were used to calculate HRs and 95% CIs in each treatment arm or biomarker subgroup.”

paraphrase[Results, Baseline molecular profiling]

“P = 0.001”

“hazard ratio (HR), 0.37 (95% confidence interval (CI), 0.224–0.627)”

ResultsFind in source

PASSReviewer 2· 80% conf

Statistical methods are comprehensive and appropriate, with named tests, effect sizes with CIs, and software identified, though exact p-values are not always reported.

Evidence

paraphrase[Methods, Statistical analysis]

“Cox proportional hazards models were used to calculate HRs and 95% CIs in each treatment arm or biomarker subgroup.”

paraphrase[Results, Associations of CRC subtypes and biomarkers with OS benefit]

“Patients with wild-type TP53 showed greater OS benefit with Enco+Cetux (hazard ratio (HR), 0.37 (95% confidence interval (CI), 0.224–0.627) for wild type and 0.76 (95% CI, 0.547–1.060) for mutant; P interaction = 0.0276).”

“Statistical analyses were done using SAS v.9.4 or R v.4.0 and above.”

Statistical analysisFind in source

The data availability statement provides a concrete route: data can be requested from Pfizer via a secure portal with conditions and timeframe. This meets the criteria for reported_and_adequate. Repository deposit and accession numbers are not applicable for patient-level data. Code sharing is not applicable as no custom code is mentioned.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability is well described with a concrete access route via Pfizer's data-sharing portal, and code is not applicable as no custom code is mentioned.

Evidence

“Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions and exceptions, Pfizer may also provide access to the related individual deidentified participant data.”

Data availabilityFind in source

PASSReviewer 2· 90% conf

Data availability is clearly stated with a concrete access mechanism via Pfizer's data-sharing portal, which is appropriate for individual patient data.

Evidence

Data availabilityFind in source

“Data may be requested from Pfizer trials 24 months after study completion. The BEACON CRC study was completed in November 2022. The deidentified participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal.”

Data availabilityFind in source

The trial is registered (NCT02928224). Methods are detailed enough for replication. Limitations are discussed. Conclusions are proportional. Funding and COI are provided. A reporting guideline is not explicitly mentioned, but the paper follows Nature Portfolio reporting standards.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Reporting is transparent with trial registration, detailed methods, limitations discussed, and funding/COI statements, though a reporting guideline is not explicitly mentioned.

Evidence

“ClinicalTrials.gov registration: NCT02928224”

AbstractFind in source

paraphrase[Discussion, paragraph 10]

“A key limitation of this biomarker analysis is its retrospective nature; the biomarkers predictive of response and resistance to Enco+Cetux±Bini, in BRAF-V600E-mutant CRC need to be further evaluated prospectively.”

“The BEACON CRC trial was sponsored by Pfizer and was conducted with support from Merck KGaA, Darmstadt, Germany (for sites outside of North America), ONO Pharmaceutical and Pierre Fabre.”

AcknowledgementsFind in source

PASSReviewer 2· 85% conf

The manuscript is transparent, with detailed methods, trial registration, discussion of limitations, and proportional conclusions, though a reporting guideline is not explicitly mentioned.

Evidence

“ClinicalTrials.gov registration: NCT02928224”

AbstractFind in source

paraphrase[Discussion, paragraph 10]

“The BEACON CRC trial was sponsored by Pfizer and was conducted with support from Merck KGaA, Darmstadt, Germany (for sites outside of North America), ONO Pharmaceutical and Pierre Fabre.”

AcknowledgementsFind in source

Registered (4 IDs: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

1 finding · worst low

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

Checked 57 references by DOI: 50 verified — 1 DOI unresolved, 6 no DOI (shown, not verified).

6 data/code links checked; 6 live.

Copyediting

6 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 6 minor suggestions below.

6 copyedit issues flagged: mostly consistency.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and well-reported. An informed reader should weigh the retrospective nature of the biomarker analysis, the lack of power analysis for exploratory endpoints, and the minor reporting gaps. No erratum is warranted based on the identified issues, but the flagged reference should be verified.

1.
HIGHreporting
Verify the reference 'BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies' (DOI 10.3978/j.issn.2078-6891.2015.077) which was not found in Crossref/OpenAlex; correct or replace it if it is erroneous or fabricated.
A reference that cannot be located in any registry is a potential fabrication signal and must be resolved before submission.
2.
MEDIUMrigor
In the Methods, specify the randomization method (e.g., central randomization, block size) to fully address randomization_method.
Both reviewers flagged the randomization method as not detailed; specifying it improves reproducibility.
3.
MEDIUMrigor
In the Methods, provide a power analysis for the biomarker analyses, or explicitly state that the study was not powered for these exploratory endpoints.
Both reviewers noted the lack of power analysis for biomarker endpoints; stating this limitation is important for interpretation.
4.
MEDIUMstatistics
In the Methods, explicitly state that assumptions for statistical tests (e.g., proportional hazards) were verified, or describe how violations were handled.
Reviewer 1 flagged assumptions_verified as inadequate; documenting assumption checks strengthens statistical rigor.
5.
MEDIUMstatistics
In the Results, report exact p-values (e.g., P = 0.0276) instead of thresholds (e.g., P < 0.0001) where possible.
Reviewer 2 noted that exact p-values are not always reported; exact values improve transparency.
6.
MEDIUMreporting
In the Reporting Summary, explicitly mention adherence to a reporting guideline such as CONSORT or STROBE.
Both reviewers flagged the absence of an explicit reporting guideline; referencing one improves transparency.
7.
MEDIUMdata code
In the Data availability, consider depositing non-identifiable aggregate data (e.g., gene expression matrices) in a public repository to enhance repository_deposit.
Reviewer 2 suggested this to improve data accessibility beyond the managed-access portal.
8.
LOWcopyedit
Fix inconsistent spacing in gene names: change 'BRAF -V600E-mutant' to 'BRAF-V600E-mutant' in the Abstract and Results (Fig. 2 legend).
Copyedit flagged inconsistent spacing around hyphens in gene names.
9.
LOWcopyedit
Ensure gene names such as TET2 are italicized in the Methods (WES and analysis).
Copyedit flagged that gene names should be italicized for consistency.

Full text (65,099 chars)Analyzed: Aug 16, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial.

Kopetz S, Murphy DA, Pu J, Ciardiello F, Desai J, Van Cutsem E, Wasan HS, Yoshino T, Saffari H, Zhang X, Hamilton P, Xie T, Yaeger R, Tabernero J

Read full text (PMC)

DOI

10.1038/s41591-024-03235-9

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/db08a7c9-3aab-4dc3-855e-6c6976ba67f2" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/db08a7c9-3aab-4dc3-855e-6c6976ba67f2/badge" alt="Kaimen Rigor review — 2.75★ (Weak), 0 critical, 1 high issue for “Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

f85f1bd1b818bf08bae6e62fef33f256349d4d4fe0b0e38fe343c468f60e3e98

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
CitationsUnresolved reference−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy claim is based on overall survival (OS) from the BEACON CRC trial, which is a hard clinical outcome. However, the biomarker analyses presented in this manuscript focus on surrogate endpoints such as immune gene signatures, cytolytic score, and molecular subtypes as predictors of OS benefit. These surrogates are not validated as substitutes for clinical outcomes, and the manuscript does not provide evidence linking these biomarkers to clinical benefit beyond exploratory associations. The claim that 'higher immune signatures showed a trend towards increased OS benefit' is based on a surrogate (immune signature) without established validation for predicting clinical outcomes in this context.
“Tumors with higher immune signatures showed a trend towards increased OS benefit with Enco+Bini+Cetux.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The manuscript reports hazard ratios for OS benefit in subgroups, but the primary effect size for the efficacy claim is not explicitly anchored to a minimal clinically important difference or a meaningful magnitude. For example, the HR for OS with Enco+Cetux versus control in TP53 wild-type is 0.37, but the manuscript does not discuss whether this is clinically meaningful. Additionally, the biomarker associations are exploratory and not presented with effect sizes that are clearly clinically significant. The manuscript states 'trend towards increased OS benefit' without providing a clear magnitude of benefit that is clinically meaningful.
“Patients with wild-type TP53 showed greater OS benefit with Enco+Cetux (hazard ratio (HR), 0.37 (95% confidence interval (CI), 0.224–0.627) for wild type and 0.76 (95% CI, 0.547–1.060) for mutant; P interaction = 0.0276)”
Find in source
03Other integrity concern
mediumAuthenticityreviewer-assessedFull detail
Trial NCT04017650 was first submitted to ClinicalTrials.gov on 2019-07-10, after the registered study start date of 2019-06-14. Retrospective registration means the protocol and outcomes were not on the public record before the study ran, which is what prospective registration exists to establish.
NCT04017650
reviewer’s wording

Findings by category

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

Overstated conclusions

2 findings · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

7 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

1 finding · worst medium

Other integrity concernAssessed

2 integrity concerns flagged (0 high).

Reporting gaps

None found

Checked — nothing surfaced.

Eight Dimensions8 pass

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior research on BRAF-V600E-mutant mCRC, the BEACON CRC trial results, and the need to understand biomarkers of response and resistance.

Evidence

paraphrase[Introduction, paragraph 1]

“BRAF-V600E mutations occur in approximately 10% of tumors in patients with mCRC and are associated with poor prognosis relative to wild-type BRAF tumors.”

“The objective of this analysis was to identify molecular correlates of clinical outcomes and define resistance mechanisms acquired following treatment.”

Introduction ¶3Find in source

Introduction ¶2Find in source

PASSReviewer 2· 90% conf

Evidence

paraphrase[Introduction, paragraph 1]

“BRAF-V600E mutations occur in approximately 10% of tumors in patients with mCRC and are associated with poor prognosis relative to wild-type BRAF tumors.”

Introduction ¶2Find in source

“The objective of this analysis was to identify molecular correlates of clinical outcomes and define resistance mechanisms acquired following treatment.”

Introduction ¶2Find in source

Sub-criteria

controlsADEQUATE

power analysisINADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodINADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Evidence

MethodsFind in source

“PFS, assessed by blinded independent central review and investigators, was defined as the time from randomization to the earliest documented disease progression or death due to any cause.”

MethodsFind in source

paraphrase[Methods, Statistical analysis]

“Calculation of the overall sample size required for the primary endpoints, statistical testing schemes and preplanned interim analysis was described previously.”

PASSReviewer 2· 85% conf

Evidence

“The BEACON CRC trial was a global, multicenter, randomized, open-label phase 3 trial.”

MethodsFind in source

“PFS, assessed by blinded independent central review and investigators, was defined as the time from randomization to the earliest documented disease progression or death due to any cause.”

MethodsFind in source

paraphrase[Methods, Study design and participants]

“Patients with histologically or cytologically confirmed, mCRC with the BRAF-V600E mutation who had disease progression after one or two previous treatment regimens were enrolled.”

Sub-criteria

demographicsINADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Biological variables are well reported, including sex, age, and demographics, though some details like race/ethnicity are not explicitly mentioned.

Evidence

paraphrase[Results, BEACON CRC biomarker analysis set]

“Paraphrase: Patient characteristics including sex and age are shown in Supplementary Table 1.”

absence[Results, BEACON CRC biomarker analysis set]

Demographics are not fully detailed in the main text.

PASSReviewer 2· 80% conf

Demographic and clinical characteristics are reported, including age, sex, and other baseline factors, though not all are detailed in the main text.

Evidence

“Heatmap of patient characteristics and molecular profiling coverage in the biomarker analysis set, across treatment arms.”

Figure 1BFind in source

Statistical analysisFind in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals are clearly documented, including IRB approval, informed consent, and regulatory compliance.

Evidence

paraphrase[Methods, Ethics statement]

“The trial was approved by the institutional review board or independent ethics committee at each center.”

“All patients provided written informed consent.”

EthicsFind in source

PASSReviewer 2· 95% conf

Ethical approval is clearly documented with a named ethics body, informed consent, and regulatory compliance.

Evidence

paraphrase[Methods, Ethics statement]

“The trial was approved by the institutional review board or independent ethics committee at each center.”

“All patients provided written informed consent.”

EthicsFind in source

paraphrase[Methods, Ethics statement]

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Key resources are well identified, including the investigational drugs, sequencing platforms, and software tools, though some details like lot numbers are not provided.

Evidence

paraphrase[Methods, Study design and participants]

“Encorafenib was administered at a dose of 300 mg daily; binimetinib at 45 mg twice daily; cetuximab at 400 mg m−2 as an initial dose, then 250 mg m−2 weekly.”

paraphrase[Methods, WES and analysis]

paraphrase[Methods, Molecular subtyping]

“CMSs were assigned to each sample using the CMSclassifier package v.1.0.0.”

PASSReviewer 2· 85% conf

Key resources, including investigational drugs, sequencing platforms, and software, are identified with sufficient detail.

Evidence

paraphrase[Methods, Study design and participants]

“Encorafenib was administered at a dose of 300 mg daily; binimetinib at 45 mg twice daily; cetuximab at 400 mg m−2 as an initial dose, then 250 mg m−2 weekly.”

paraphrase[Methods, WES and analysis]

paraphrase[Methods, Molecular subtyping]

“CMSs were assigned to each sample using the CMSclassifier package v.1.0.0.”

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedINADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 80% conf

Statistical methods are appropriate and well described, with exact p-values and effect sizes with confidence intervals reported, though some assumptions are not explicitly verified.

Evidence

paraphrase[Methods, Statistical analysis]

“Cox proportional hazards models were used to calculate HRs and 95% CIs in each treatment arm or biomarker subgroup.”

paraphrase[Results, Baseline molecular profiling]

“P = 0.001”

“hazard ratio (HR), 0.37 (95% confidence interval (CI), 0.224–0.627)”

ResultsFind in source

PASSReviewer 2· 80% conf

Statistical methods are comprehensive and appropriate, with named tests, effect sizes with CIs, and software identified, though exact p-values are not always reported.

Evidence

paraphrase[Methods, Statistical analysis]

“Cox proportional hazards models were used to calculate HRs and 95% CIs in each treatment arm or biomarker subgroup.”

paraphrase[Results, Associations of CRC subtypes and biomarkers with OS benefit]

“Statistical analyses were done using SAS v.9.4 or R v.4.0 and above.”

Statistical analysisFind in source

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability is well described with a concrete access route via Pfizer's data-sharing portal, and code is not applicable as no custom code is mentioned.

Evidence

Data availabilityFind in source

PASSReviewer 2· 90% conf

Data availability is clearly stated with a concrete access mechanism via Pfizer's data-sharing portal, which is appropriate for individual patient data.

Evidence

Data availabilityFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Reporting is transparent with trial registration, detailed methods, limitations discussed, and funding/COI statements, though a reporting guideline is not explicitly mentioned.

Evidence

“ClinicalTrials.gov registration: NCT02928224”

AbstractFind in source

paraphrase[Discussion, paragraph 10]

“The BEACON CRC trial was sponsored by Pfizer and was conducted with support from Merck KGaA, Darmstadt, Germany (for sites outside of North America), ONO Pharmaceutical and Pierre Fabre.”

AcknowledgementsFind in source

PASSReviewer 2· 85% conf

The manuscript is transparent, with detailed methods, trial registration, discussion of limitations, and proportional conclusions, though a reporting guideline is not explicitly mentioned.

Evidence

“ClinicalTrials.gov registration: NCT02928224”

AbstractFind in source

paraphrase[Discussion, paragraph 10]

“The BEACON CRC trial was sponsored by Pfizer and was conducted with support from Merck KGaA, Darmstadt, Germany (for sites outside of North America), ONO Pharmaceutical and Pierre Fabre.”

AcknowledgementsFind in source

Registered (4 IDs: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

1 finding · worst low

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

Checked 57 references by DOI: 50 verified — 1 DOI unresolved, 6 no DOI (shown, not verified).

6 data/code links checked; 6 live.

Copyediting

6 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 6 minor suggestions below.

6 copyedit issues flagged: mostly consistency.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHreporting
Verify the reference 'BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies' (DOI 10.3978/j.issn.2078-6891.2015.077) which was not found in Crossref/OpenAlex; correct or replace it if it is erroneous or fabricated.
A reference that cannot be located in any registry is a potential fabrication signal and must be resolved before submission.
2.
MEDIUMrigor
In the Methods, specify the randomization method (e.g., central randomization, block size) to fully address randomization_method.
Both reviewers flagged the randomization method as not detailed; specifying it improves reproducibility.
3.
MEDIUMrigor
In the Methods, provide a power analysis for the biomarker analyses, or explicitly state that the study was not powered for these exploratory endpoints.
Both reviewers noted the lack of power analysis for biomarker endpoints; stating this limitation is important for interpretation.
4.
MEDIUMstatistics
In the Methods, explicitly state that assumptions for statistical tests (e.g., proportional hazards) were verified, or describe how violations were handled.
Reviewer 1 flagged assumptions_verified as inadequate; documenting assumption checks strengthens statistical rigor.
5.
MEDIUMstatistics
In the Results, report exact p-values (e.g., P = 0.0276) instead of thresholds (e.g., P < 0.0001) where possible.
Reviewer 2 noted that exact p-values are not always reported; exact values improve transparency.
6.
MEDIUMreporting
In the Reporting Summary, explicitly mention adherence to a reporting guideline such as CONSORT or STROBE.
Both reviewers flagged the absence of an explicit reporting guideline; referencing one improves transparency.
7.
MEDIUMdata code
In the Data availability, consider depositing non-identifiable aggregate data (e.g., gene expression matrices) in a public repository to enhance repository_deposit.
Reviewer 2 suggested this to improve data accessibility beyond the managed-access portal.
8.
LOWcopyedit
Fix inconsistent spacing in gene names: change 'BRAF -V600E-mutant' to 'BRAF-V600E-mutant' in the Abstract and Results (Fig. 2 legend).
Copyedit flagged inconsistent spacing around hyphens in gene names.
9.
LOWcopyedit
Ensure gene names such as TET2 are italicized in the Methods (WES and analysis).
Copyedit flagged that gene names should be italicized for consistency.

Full text (65,099 chars)Analyzed: Aug 16, 2026